Diabetic Neuropathic Pain - Pipeline Review, H2 2015 Now Available at iData Insights Diabetic Neuropathic Pain - Pipeline Review, H2 2015 Summary Global Markets Direct s, Diabetic Neuropathic Pain - Pipeline Review, H2 2015, provides an overview of the Diabetic Neuropathic Pain s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Neuropathic Pain and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain - Plan mergers and acquisitions effectively by 1
identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124216/metastatic-liver-cancer-pipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124216/metastatic-liver-cancer-pipeline-review-h2-2015 Table of Contents able of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Diabetic Neuropathic Pain Overview 9 Therapeutics Development 10 Pipeline Products for Diabetic Neuropathic Pain - Overview 10 Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11 Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12 Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 15 Diabetic Neuropathic Pain - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Diabetic Neuropathic Pain - Products under Development by Companies 19 Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 20 Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 21 Astellas Pharma Inc. 21
2
AstraZeneca Plc 22 BioDelivery Sciences International, Inc. 23 Boehringer Ingelheim GmbH 24 Daiichi Sankyo Company, Limited 25 Dong-A Socio Group 26 Eli Lilly and Company 27 Glenmark Pharmaceuticals Ltd. 28 Hydra Biosciences, Inc. 29 Immune Pharmaceuticals Inc. 30 Laboratorios Del Dr. Esteve S.A. 31 Lohocla Research Corporation 32 Mertiva AB 33 Novaremed 34 Pharmaleads 35 RAPID Pharmaceuticals AG 36 Relmada Therapeutics, Inc. 37 Sphaera Pharma Pvt. Ltd. 38 Theravasc, Inc. 39 Diabetic Neuropathic Pain - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Combination Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 (amitriptyline + ketamine hydrochloride) - Drug Profile 50 3
Product Description 50 Mechanism of Action 50 R&D Progress 50 (diclofenac sodium + triclocarban) - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 AS-1069562 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ASP-3662 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AZD-5213 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 clonidine hydrochloride - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 duloxetine hydrochloride DR - Drug Profile 58 Product Description 58 Mechanism of Action 58
4
R&D Progress 58 E-52862 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 filgrastim - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 GERPOOI - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 GRC-17536 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 HC-030031 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Kindolor - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 mepivacaine hydrochloride - Drug Profile 69 Product Description 69 5
Mechanism of Action 69 R&D Progress 69 mirogabalin besylate - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NG2-GAD - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NRD-135SE1 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 PGN-305 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 PL-37 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 RAP-103 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76
6
RAP-104 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 sodium nitrite SR - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Diabetic Neuropathic Pain - Recent Pipeline Updates 81 Diabetic Neuropathic Pain - Dormant Projects 90 Diabetic Neuropathic Pain - Discontinued Products 93 Diabetic Neuropathic Pain - Product Development Milestones 95 Featured News & Press Releases 95 Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 95 Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy 96 Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 96 Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 97 Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy 98 Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy 98
7
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 99 Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 99 Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan 100 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102 Read More http://www.idatainsights.com/reports-landing-page.php?id=124216/metastatic-livercancer-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
8
9